Table 2.
In vitro studies of neutrophil ability for killing or restricting the growth of NTM
| Organism | Host | Neutrophil purification | Experimental Read out | Observation | Killing / Restriction | Study reference |
|---|---|---|---|---|---|---|
| M. avium | Human (HIV) | Ficoll gradient 98–99% purity confirmed by microscopy | Radiometric assay (Bactec) | Isolated neutrophils from AIDS patients responded to exogenously supplied G-CSF by inhibiting the growth of mycobacteria | R 3–10 days | [53] |
| M. avium | Human | Ficoll sedimentation Purity NR | CFU | Half of the bacteria phagocytosed at 15 min were killed by neutrophils at 45 min, and killing was nearly complete at 120 min | K 2 h | [54] |
| M. avium | Mouse | Ficoll gradient > 97% purity confirmed by microscopy | CFU | Neutrophils from mice treated with G-CSF were able to kill M. avium ex vivo, compared with controls | K 4 h | [40] |
| M. fortuitum | Human | Ficoll gradient Purity NR | CFU | Killing of mycobacteria in the presence of serum, however no killing occurred in the absence of serum | K 2 h | [55] |
| M. smegmatis | Human | Percoll, > 99% purity confirmed by haematoxylin staining | CFU | Neutrophils’ antibacterial capacities demonstrated with efficient killing of mycobacteria | K Up to 6 h | [56] |
| M. abscessus | Human | Percoll, > 98% purity confirmed by microscopy | CFU | Mycobacteria activated the neutrophils’ bacterial clearance mechanisms, including ROS generation, NET formation, and phagocytosis | K 1 h | [57] |
K Killing (reduction of CFU number), NR Not recorded, R Restriction (slower increase of CFU)